The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

Oncotarget

Volumn 6, Issue 22, 2015, Pages 18875-18890

  Ordóñez, José Luis ^a,d   Amaral, Ana Teresa ^a,d   Carcaboso, Angel M ^b   Herrero Martín, David ^c   Del Carmen García Macías, María ^d   Sevillano, Vicky ^d   Alonso, Diego ^d   Pascual Pasto, Guillem ^b   San Segundo, Laura ^d   Vila Ubach, Monica ^b   Rodrigues, Telmo ^d   Fraile, Susana ^d   Teodosio, Cristina ^d   Mayo Iscar, Agustín ^e   Aracil, Miguel ^f   Galmarini, Carlos María ^f   Tirado, Oscar M ^c   Mora, Jaume ^b   de Álava, Enrique ^a,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e UNIVERSITY OF VALLADOLID   (Spain)

^f Cell Biology Department   (Spain)

Author keywords

DNA damage; Ewing sarcoma; PARP inhibitor; PDX models; Trabectedin

Indexed keywords

CASPASE 3; CASPASE 7; DNA; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; TRABECTEDIN; VELIPARIB; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASE REPORT; CELL PROLIFERATION; CHROMOSOME 1Q; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR XENOGRAFT; YOUNG ADULT; ANIMAL; CHILD; DRUG SCREENING; GENETICS; NONOBESE DIABETIC MOUSE; PATHOLOGY; RANDOMIZATION; SARCOMA, EWING; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHILD; DIOXOLES; DNA DAMAGE; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RANDOM ALLOCATION; SARCOMA, EWING; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938853305     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4303     Document Type: Article

References (34)

1. Amaral AT, Ordonez JL, Otero-Motta AP, Garcia-Dominguez DJ, Sevillano MV and de Alava E. Innovative therapies in ewing sarcoma. Adv Anat Pathol. 2014; 21: 49-67.
2. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A and Jurgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28: 3284-91.
3. Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, van den Berg H, Juergens H and Dirksen U. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010; 116: 443-50.
4. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012; 31: 1287-98.
5. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer cell. 2011; 19: 664-78.
6. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA and Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer research. 2012; 72: 1608-13.
7. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483: 570-5.
8. Mangerich A and Burkle A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. International journal of cancer. 2011; 128: 251-65.
9. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 2010; 31: 955-60.
10. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB, 3rd, Bahrami A, Pappo A, Wu J, Loh A, et al. Targeting the DNA repair pathway in ewing sarcoma. Cell Rep. 2014; 9: 829-40.
11. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Molecular cancer therapeutics. 2009; 8: 449-57.
12. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J and Helman LJ. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (New York, NY. 2011; 13: 145-53.
13. Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordonez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, et al. Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clin Cancer Res. 2015; 21: 1373-82.
14. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A and Helman LJ. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2013; 20: 1190-203.
15. Chou TC, Motzer RJ, Tong Y and Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. Journal of the National Cancer Institute. 1994; 86: 1517-24.
16. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
17. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4: 998-1013.
18. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME and Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer research. 1990; 50: 38-43.
19. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-7.
20. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917-21.
21. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014; 4: 1326-41.
22. Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG and Yoon SS. Combining PARP-1 inhibition and radiation in ewing sarcoma results in lethal DNA damage. Molecular cancer therapeutics. 2013; 12: 2591-600.
23. He JX, Yang CH and Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin. 2010; 31: 1172-80.
24. Mateo J, Ong M, Tan DS, Gonzalez MA and de Bono JS. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol. 2013; 10: 688-96.
25. Burdach S. Molecular precision chemotherapy: overcoming resistance to targeted therapies? Clin Cancer Res. 2014; 20: 1064-6.
26. Scott CL, Becker MA, Haluska P and Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013; 3: 295.
27. Scott CL, Mackay HJ and Haluska P, Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014: e258-66.
28. Beltran AL, Ordonez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Kirkali Z, Cheng L, Montironi R, Prieto R and De Alava E. Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma. J Biol Regul Homeost Agents. 2013; 27: 559-67.
29. Lopez-Beltran A, Ordonez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Munoz E, Cheng L, Montironi R and de Alava E. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch. 2010; 457: 555-61.
30. Amaral AT, Manara MC, Berghuis D, Ordonez JL, Biscuola M, Lopez-Garcia MA, Osuna D, Lucarelli E, Alviano F, Lankester A, Scotlandi K and de Alava E. Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications. PLoS ONE. 2014; 9: e85814.
31. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gurpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. British journal of cancer. 2009; 101: 80-90.
32. Martins AS, Ordonez JL, Garcia-Sanchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gurpide J and de Alava E. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer research. 2008; 68: 6260-70.
33. Huertas-Martinez J, Rello-Varona S, Herrero-Martin D, Barrau I, Garcia-Monclus S, Sainz-Jaspeado M, Lagares-Tena L, Nunez-Alvarez Y, Mateo-Lozano S, Mora J, Roma J, Toran N, Moran S, et al. Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget. 2014; 5: 9744-55.
34. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric blood & cancer. 2007; 49: 928-40.